Antimicrobial Applications of Inclusion Bodies.
Antimicrobial activity
Antimicrobials
Inclusion body
Protein nanoparticles
Recombinant proteins
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
19
1
2023
pubmed:
20
1
2023
medline:
24
1
2023
Statut:
ppublish
Résumé
A broad number of inclusion bodies (IBs) potential uses, including biocatalysis, biocompatible nanomaterials, and nanopills for biomedicine, have been described so far. Recently, it has also been shown that they can also be used as antimicrobial agents. Here, we describe the protocol used to produce and purify IBs with antimicrobial activity at desirable yields and also an optimized and simple methodology to determine the antimicrobial activity of IBs against bacterial strains.
Identifiants
pubmed: 36656531
doi: 10.1007/978-1-0716-2930-7_19
doi:
Substances chimiques
Anti-Infective Agents
0
Recombinant Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-269Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Rinas U, Garcia-Fruitós E, Corchero JL et al (2017) Bacterial inclusion bodies: discovering their better half. Trends Biochem Sci 42(9):726–737
doi: 10.1016/j.tibs.2017.01.005
Gifre-Renom L, Seras-Franzoso J, Rafael D et al (2020) The biological potential hidden in inclusion bodies. Pharmaceutics 12(2):157
doi: 10.3390/pharmaceutics12020157
Gifre-Renom L, Ugarte-Berzal E, Martens E et al (2020) Recombinant protein-based nanoparticles: elucidating their inflammatory effects in vivo and their potential as a new therapeutic format. Pharmaceutics 12(5):450
doi: 10.3390/pharmaceutics12050450
Cano-Garrido O, Rodríguez-Carmona E, Díez-Gil C et al (2013) Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies. Acta Biomater 9(4):6134–6142
doi: 10.1016/j.actbio.2012.11.033
Köszagová R, Hrabárová E, Achbergerová L et al (2022) Insoluble protein applications: the use of bacterial inclusion bodies as biocatalysts. Methods Mol Biol 2406:501–515
doi: 10.1007/978-1-0716-1859-2_30
de Marco A, Ferrer-Miralles N, Garcia-Fruitós E et al (2019) Bacterial inclusion bodies are industrially exploitable amyloids. FEMS Microbiol Rev 43(1):53–72
doi: 10.1093/femsre/fuy038
Roessl U, Nahálka J, Nidetzky B (2010) Carrier-free immobilized enzymes for biocatalysis. Biotechnol Lett 32(3):341–350
doi: 10.1007/s10529-009-0173-4
Seras-Franzoso J, Tsimbouri PM, Burgess KV et al (2014) Topographically targeted osteogenesis of mesenchymal stem cells stimulated by inclusion bodies attached to polycaprolactone surfaces. Nanomedicine (Lond) 9(2):207–220
doi: 10.2217/nnm.13.43
Torrealba D, Parra D, Seras-Franzoso J et al (2016) Nanostructured recombinant cytokines: a highly stable alternative to short-lived prophylactics. Biomaterials 107:102–114
doi: 10.1016/j.biomaterials.2016.08.043
Céspedes MV, Cano-Garrido O, Álamo P et al (2020) Engineering secretory amyloids for remote and highly selective destruction of metastatic foci. Adv Mater 32(7):e1907348
doi: 10.1002/adma.201907348
Roca-Pinilla R, López-Cano A, Saubi C et al (2020) A new generation of recombinant polypeptides combines multiple protein domains for effective antimicrobial activity. Microb Cell Factories 19(1):122
doi: 10.1186/s12934-020-01380-7